This finding gives rise to the conclusion that iron supplementation for pregnant women in tropical regions may carry unrecognized risks and should be validated in large-scale clinical trials.
We reanalyzed data from a crosssectional survey conducted in 1998 among 530 pregnant women in southern Ghana, an area of malaria holoendemicity [5] . Preceding the implementation of intermittent preventive treatment, almost 2 of 3 women attending antenatal care clinics in this area harbored P. falciparum, as evidenced by PCR analysis of peripheral blood samples, positive results of which almost invariably correspond to placental infection [6] . By use of the definition of iron deficiency (i.e., a ferritin level of Ͻ30 ng/mL, or Ͻ70 ng/mL if the C-reactive protein level was Ͼ8.2 ng/mL) and statistical analyses specified by Kabyemela et al. [4] , we found that iron deficiency reduced the risk of P. falciparum infection in pregnant Ghanaian women by 33% ( [4] . No data on ferritin levels were available for samples from 3 women. [4] in an area of higher malaria endemicity (and lower iron deficiency prevalence) in West Africa. However, a methodological problem remains. Serum ferritin level is considered the most useful laboratory measure of iron status, but a well-known limitation is its increase in patients with inflammation, including that due to malaria. The degree of elevation in the C-reactive protein level that invalidates use of ferritin level as the criterion of iron deficiency has not been accurately defined [7] . To address this problem, we used the following 3 definitions of iron deficiency in our initial report: a ferritin level of Ͻ12 ng/mL [8] ; a ferritin level of Ͻ12 ng/mL, or 50 ng/mL if the C-reactive protein level was Ͼ6 ng/mL [9] ; and a ferritin level of Ͻ30 ng/mL [10] . These definitions yielded iron deficiency prevalences of 5%, 18%, and 26%, respectively. For these classifications of iron status, concordance with the definition used by Kabyemela et al. [4] was 67%, 76%, and 88%, respectively. Repeated multivariate analysis with these initial categorizations of iron status revealed that the risk of P. falciparum infection was greatly reduced among women classified as iron deficient by the most robust definition (i.e., a ferritin level of Ͻ12 ng/mL; adjusted OR, 0.22; 95% CI, 0.09 -0.54), among women with a ferritin concentration of Ͻ30 ng/mL (adjusted OR, 0.33; 95% CI, 0.22-0.50), but not among women with a ferritin level of Ͻ12 ng/mL, or 50 ng/mL if the C-reactive protein level was Ͼ6 ng/mL (adjusted OR, 1.01; 95% CI, 0.63-1.60) (table 1). We do not consider this latter finding as evidence of a spurious association. Rather, it underscores the difficulty in reliably defining iron deficiency in pregnant women exposed to P. falciparum and other infectious diseases, which may eventually mask actual associations. Kabyemela et al. [4] call for clinical trials to guide the use of iron supplementation in pregnant women living in malariaendemic regions. Our data support this and, additionally, highlight the need for evaluating diagnostic means of determining iron deficiency in this risk group.
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